MX2021016001A - Proceso para fabricar 3,5-difluoro-benzilamida de acido (s)-3-hidroxi-1-(1h-indol-5-il)-2-oxo-pirrolidina-3-carboxilico. - Google Patents

Proceso para fabricar 3,5-difluoro-benzilamida de acido (s)-3-hidroxi-1-(1h-indol-5-il)-2-oxo-pirrolidina-3-carboxilico.

Info

Publication number
MX2021016001A
MX2021016001A MX2021016001A MX2021016001A MX2021016001A MX 2021016001 A MX2021016001 A MX 2021016001A MX 2021016001 A MX2021016001 A MX 2021016001A MX 2021016001 A MX2021016001 A MX 2021016001A MX 2021016001 A MX2021016001 A MX 2021016001A
Authority
MX
Mexico
Prior art keywords
benzylamide
indol
difluoro
oxo
hydroxy
Prior art date
Application number
MX2021016001A
Other languages
English (en)
Inventor
Jeyaprakashnarayanan Seenisamy
Timo Heinrich
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of MX2021016001A publication Critical patent/MX2021016001A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/547—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame spiro-condensed or forming part of bridged ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

Un proceso para la fabricación de 3,5-difluoro-benzilamida de ácido (S)-3-hidroxi-1-(1H-indol-5-il)-2-oxo-pirrolidin-3-carboxíli co.
MX2021016001A 2019-07-03 2020-06-30 Proceso para fabricar 3,5-difluoro-benzilamida de acido (s)-3-hidroxi-1-(1h-indol-5-il)-2-oxo-pirrolidina-3-carboxilico. MX2021016001A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19184056 2019-07-03
PCT/EP2020/068317 WO2021001328A1 (en) 2019-07-03 2020-06-30 Process for manufacturing (s)-3-hydroxy-1-(1h-indol-5-yl)-2-oxo-pyrrolidine-3-carboxylic acid 3,5-difluoro-benzylamide

Publications (1)

Publication Number Publication Date
MX2021016001A true MX2021016001A (es) 2022-01-24

Family

ID=67145670

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021016001A MX2021016001A (es) 2019-07-03 2020-06-30 Proceso para fabricar 3,5-difluoro-benzilamida de acido (s)-3-hidroxi-1-(1h-indol-5-il)-2-oxo-pirrolidina-3-carboxilico.

Country Status (20)

Country Link
US (1) US20220251072A1 (es)
EP (1) EP3994134B9 (es)
JP (1) JP2022538364A (es)
KR (1) KR20220028030A (es)
CN (1) CN114026069A (es)
AU (1) AU2020299711A1 (es)
BR (1) BR112021026624A2 (es)
CA (1) CA3145579A1 (es)
DK (1) DK3994134T3 (es)
FI (1) FI3994134T3 (es)
HR (1) HRP20240534T1 (es)
IL (1) IL289479A (es)
LT (1) LT3994134T (es)
MX (1) MX2021016001A (es)
PL (1) PL3994134T3 (es)
PT (1) PT3994134T (es)
RS (1) RS65436B1 (es)
SI (1) SI3994134T1 (es)
TW (1) TW202116756A (es)
WO (1) WO2021001328A1 (es)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102010048374A1 (de) 2010-10-13 2012-04-19 Merck Patent Gmbh Pyrrolidinone als MetAP-2 Inhibitoren
DE102012006884A1 (de) 2012-04-04 2013-10-10 Merck Patent Gmbh Cyclische Amide als MetAP-2 Inhibitoren
CA2957154C (en) 2014-08-04 2023-01-10 Merck Patent Gmbh Pyrrolidinone derivatives as metap-2 inhibitors
ES2923002T3 (es) * 2015-02-11 2022-09-22 Theravance Biopharma R&D Ip Llc Acido (2S,4R)-5-(5'-cloro-2'-fluorobifenil-4-il)-4-(etoxioxailamino)-2-hidroximetil-2-metilpentanoico como inhibidor de la neprilisina
WO2016133803A1 (en) * 2015-02-19 2016-08-25 Theravance Biopharma R&D Ip, Llc (2r,4r)-5-(5'-chloro-2'-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid

Also Published As

Publication number Publication date
DK3994134T3 (da) 2024-04-15
EP3994134B9 (en) 2024-06-26
HRP20240534T1 (hr) 2024-07-05
EP3994134B1 (en) 2024-01-24
WO2021001328A1 (en) 2021-01-07
PL3994134T3 (pl) 2024-06-17
RS65436B1 (sr) 2024-05-31
PT3994134T (pt) 2024-04-23
TW202116756A (zh) 2021-05-01
AU2020299711A1 (en) 2022-02-24
EP3994134A1 (en) 2022-05-11
BR112021026624A2 (pt) 2022-05-10
JP2022538364A (ja) 2022-09-01
CN114026069A (zh) 2022-02-08
LT3994134T (lt) 2024-05-10
CA3145579A1 (en) 2021-01-07
FI3994134T3 (fi) 2024-04-24
SI3994134T1 (sl) 2024-06-28
US20220251072A1 (en) 2022-08-11
KR20220028030A (ko) 2022-03-08
IL289479A (en) 2022-02-01

Similar Documents

Publication Publication Date Title
MY195408A (en) Novel Aspartokinase Variant and Method for Producing L- Amino Acid Using the Same
MX2020007591A (es) Homoserina deshidrogenasa modificada y procedimiento de produccion de homoserina o l-aminoacido derivado de homoserina mediante el uso de la misma.
MY195583A (en) Modified Homoserine Dehydrogenase and Method for Producing Homoserine Or L-Amino Acid Derived from Homoserine using the same
MX2021000459A (es) Metodo para producir celulas t gamma y delta.
EP3789382A4 (en) PREPARATION OF 5,5-DI-SUBSTITUTED 4,5-DIHYDROISOXAZOLE
MY197889A (en) Microorganism producing l-amino acid and method for producing l-amino acid using the same
MX2022003804A (es) Metodo de fabricacion.
EP3995475A4 (en) PROCESS FOR THE PRODUCTION OF 1,3-BUTADIENE
MX2019009214A (es) Microorganismo del genero corynebacterium que produce 5'-xantosina monofosfato y procedimiento de preparacion de 5'-xantosina monofosfato mediante el uso del mismo.
MX2019015056A (es) Variante de acetohidroxiacido sintasa, microorganismo que comprende la misma, y procedimiento de produccion de aminoacidos de cadena l-ramificada mediante el uso del mismo.
CR20220006A (es) Compuestos para tratar enfermedad respiratoria
WO2020185041A3 (ko) 세로토닌 수식 히알루론산을 포함하는 하이드로젤 및 이의 용도
MX2021016001A (es) Proceso para fabricar 3,5-difluoro-benzilamida de acido (s)-3-hidroxi-1-(1h-indol-5-il)-2-oxo-pirrolidina-3-carboxilico.
SG10201806671UA (en) Methoxycarbonylation with formic acid as co source
SA518391213B1 (ar) -l طــريـقـة لإنـــتـاج مـــيــثـيونــيــن
SA518391161B1 (ar) -l طـــريــقـة لإنــتــاج مــيــثــيـونـيـن
MX2023010436A (es) Nueva variante de citrato sintasa y procedimiento para producir l-valina utilizando la misma.
MX2020006070A (es) Proceso de producción de n-acetil taurinato de magnesio.
EP3995474A4 (en) PROCESS FOR PRODUCTION OF 1,3-BUTADIENE
EP3815703A4 (en) PROMOTER OF PRODUCTION OF INTERLEUKIN-6, 10
SA518391158B1 (ar) طريقة لإنتاج مركبتانات عن طريق التحلل الهيدروجيني لأنزيم ثنائي السلفيد بوجود الهيدروجين
ZA202108637B (en) Microorganism for producing l-amino acid having increased cytochrome c activity, and l-amino acid production method using same
IL290506A (en) Process for preparing [1.1.1]propane
MX2022005275A (es) Metodo mejorado para la fabricacion de alulosa.
IL291634A (en) Process for the preparation of 1,1'-disulfandylbis(4-fluoro-2-methyl-5-nitrobenzene)